Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

Professor Andreas Skolarikos shares his experience with the LithoVue Elite System.

Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy

Krupski is a professor of urology at the University of Virginia School of Medicine.

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.

Published data support safety, efficacy of vaginal insert for SUI

ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear. 

Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer 

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

Treatment Outcomes in Black Patients with mHSPC: New Data and Insights 

Neal D. Shore, MD, FACS, discusses how achieving ultra-low prostate-specific antigen (PSA) levels (<0.02 ng/mL) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with darolutamide plus androgen deprivation therapy in the ARANOTE trial correlates with improved clinical outcomes including progression-free survival.

The Prognostic Power of PSA: What Ultra-Low Levels Reveal in mHSPC 

Arun Azad, PhD, MBBS, discusses how matching-adjusted indirect comparison (MAIC) methodology enables the comparison of enzalutamide and darolutamide in metastatic hormone-sensitive prostate cancer (mHSPC) treatment, revealing both agents significantly improve outcomes when added to androgen deprivation therapy (ADT), with clinical decision-making guided by efficacy differences in specific populations (docetaxel-naive, disease volume) and distinct safety profiles, particularly darolutamide’s reduced central nervous system (CNS) toxicity vs enzalutamide’s more established long-term data.

Rethinking Comparisons: Novel Strategies for Evaluating Androgen Receptor Inhibitors in Prostate Cancer

discusses how recent clinical trials, including ARASENS and ARANOTE, have expanded treatment options for metastatic prostate cancer, highlighting the efficacy and safety of combining darolutamide with androgen deprivation therapy and/or chemotherapy while considering patient-specific factors to guide individualized treatment decisions.

Pedro Barata, MD, MSc FACP, discusses how recent clinical trials have advanced the treatment of metastatic prostate cancer, focusing on the efficacy of combination therapies involving radium-223, AR-targeted agents, and PARP inhibitors, while addressing safety concerns and considering optimal treatment strategies for different patient populations.

Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment

Michael Gorin, MD explores the PSMA imaging landscape, emerging agents with extended imaging windows, key copper-based imaging trials, and the anticipated impact of next-day imaging pending CLARIFY trial results.

Enhanced Detection in Prostate Cancer: The Promise of 64Cu-SAR-bisPSMA for Improved Imaging and Recurrence Reduction

Gary D. Steinberg, MD, discusses recent clinical trial data presented at the AUA 2024 Conference, as well as practice-changing novel therapies for the treatment of intermediate and high risknon muscle invasive bladder cancer.

 Innovative immunological and target therapies for NMIBC: Recent clinical trial data shaping the future

Neal Shore, MD, FACS, provides comprehensive insights on the evolving treatment landscape for patients with BCG-unresponsive non-muscle-invasive bladder cancer, with a focus on clinical research and treatment practices.

Treatment Advances in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Daniel Allan Hamstra, MD, PhD, FASTRO, FASCO, details the currently available options for rectal spacers in patients with prostate cancer undergoing radiation therapy, and highlights the key clinical trial data leading to their approval for reducing toxicities and preserving sexual quality-of-life.

The Role of Rectal Spacers in the Treatment of Prostate Cancer

Expert urologist Michael S. Leapman, MD, MHS, considers how the Decipher Prostate Genomic Classifier and real-world data updates from the 2023 American Urological Association (AUA) Annual Meeting have impacted prostate cancer care.

Genetic Testing in Prostate Cancer: Evidence from Real-World Data on Decipher

Eric A. Singer, MD, MA, FACS, an expert urologic oncologist, discusses recent data from KEYNOTE-057 presented at the 2023 American Urological Association (AUA) Annual Meeting, and offers clinical insights on treatment paradigms for non-muscle-invasive bladder cancer.

High-Risk, Non-Muscle-Invasive Bladder Cancer: Recent Updates to KEYNOTE-057 Trial Data